# Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

> **NCT00909766** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 113 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** BMS-830216
- **DRUG:** BMS-830216
- **DRUG:** BMS-830216
- **DRUG:** BMS-830216
- **DRUG:** BMS-830216
- **DRUG:** BMS-830216
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00909766
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909766, "Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00909766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*